DCVC Bio

Activity in this selectionblackstone-multi-asset-investing-14dcd2c7

By stage

Series A2

Series B1

Biotech3

United States3

3 in this selection

Jun 21

Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine

$14.4MSeries A+

Role not disclosed

May 4

Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2

$97MSeries A

Role not disclosed

Apr 8

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed